Mesalamine Capsule, Extended Release — FDA Drug Shortage

To Be Discontinued — Mylan Pharmaceuticals Inc., a Viatris Company

The FDA lists a drug shortage record for Mesalamine Capsule, Extended Release (capsule, extended release) from Mylan Pharmaceuticals Inc., a Viatris Company with status To Be Discontinued. The shortage was first posted on 08/25/2026.

Shortage Details

Status
To Be Discontinued
Company
Mylan Pharmaceuticals Inc., a Viatris Company
Package NDC
0378-1375-78
Dosage Form
Capsule, Extended Release
Presentation
Mesalamine, Capsule, Extended Release, .375 g (NDC 0378-1375-78)
Initial Posting
08/25/2026
Revised Date